drugset / Trial / NCT07554846
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC) without EGFR/ALK mutations. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1030.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2030-05-01
- Completion
- 2032-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
Indications
No indication recorded.